高级检索
当前位置: 首页 > 详情页

Chemotherapy-induced miR-141/MAP4K4 signaling suppresses progression of colorectal cancer

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Hebei Med Univ, Hosp 4, Dept Second Gen Surg, Shijiazhuang 050011, Hebei, Peoples R China [2]Hebei Med Univ, Res Ctr, Hosp 4, Shijiazhuang 050011, Hebei, Peoples R China [3]Hebei Med Univ, Pediat Surg, Hosp 2, Shijiazhuang 050011, Hebei, Peoples R China
出处:
ISSN:

摘要:
One of the treatment failures for colorectal cancer (CRC) is resistance to chemotherapy drugs. miRNAs have been demonstrated to be a new regulator of pathobiological processes in various tumors. While few studies have explored the specific role of miR-141 in mediating 5-fluorouracil (5-FU) sensitivity of CRC cells, the present study aimed to detect the contribution of miR-141 in 5-FU sensitivity. The CRC cells viability was measured by MTS assay and cell colony forming. The expression of miR-141 and its downstream targets were assessed by reverse transcription quantitative PCR, Western blotting, and immunohistochemistry. The functional assays were conducted using CRC cells and nude mice. At the present study, we found overexpression of miR-141 could inhibit proliferation, migration, tumor-forming and invasive potential of CRC cells in vitro and mitogen-activated protein kinase kinase kinase kinase 4 (MAP4K4) was verified as a directed target of miR-141. The combination treatment of miR-141 with 5-FU, directly targetting MAP4K4, could better inhibit invasion and metastasis of CRC cells colony than either one alone. Furthermore, overexpression of miR-141, targetting MAP4K4, enhanced the effected of 5-FU and suppressed the malignant biological behaviors, in vivo. Our findings showed that 5-FU inhibited malignant behavior of human CRC cells in vitro and in vivo by enhancing the efficiency of miR-141. Our data suggested that targetting the miR-141/MAP4K4 signaling pathway could be a potential molecular target that may enhance chemotherapeutic efficacy in the treatment of CRC.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2018]版:
大类 | 3 区 生物
小类 | 4 区 生化与分子生物学 4 区 细胞生物学
最新[2025]版:
大类 | 3 区 生物学
小类 | 3 区 生化与分子生物学 4 区 细胞生物学
JCR分区:
出版当年[2018]版:
Q3 CELL BIOLOGY Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY
最新[2024]版:
Q1 BIOCHEMISTRY & MOLECULAR BIOLOGY Q2 CELL BIOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2018版] 出版当年五年平均 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者机构: [1]Hebei Med Univ, Hosp 4, Dept Second Gen Surg, Shijiazhuang 050011, Hebei, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [1]Hebei Med Univ, Hosp 4, Dept Second Gen Surg, Shijiazhuang 050011, Hebei, Peoples R China [*1]Department of the Second General Surgery, The Fourth Hospital, Hebei Medical University, Shiiazhuang, Hebei, 050011,P. R. China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42329 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号